"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial looking at gene therapy for acute myeloid leukaemia and chronic myeloid leukaemia
Cancer type:
Acute leukaemia
Acute myeloid leukaemia (AML)
Blood cancers
Chronic leukaemia
Chronic myeloid leukaemia (CML)
Leukaemia
Status:
Results
Phase:
Phase 1/2
This trial looked at a treatment called T cell receptor 
. It was for people who had already had treatment for acute myeloid leukaemia (AML) or chronic myeloid leukaemia (CML).
The trial was open for people to join between 2014 and 2018. The team analysed the results in 2019.
More about this trial
Doctors often treat acute myeloid leukaemia (AML) and chronic myeloid leukaemia (CML) with chemotherapy, and sometimes a . But sometimes the leukaemia comes back.
The research team wanted to find out if T cell receptor (TCR) gene therapy is useful for people in this situation.
Doctors remove specific immune system cells (called T cells) from a person’s blood sample. Then they change (modify) the cells in the laboratory. They add a gene to the cells to help them recognise a protein called WT1. The doctors then give the person back their T cells through a drip into a vein.
Abnormal blood cells such as leukaemia cells often have a high level of WT1. Other cells in the body usually have a very low level of WT1. Researchers hoped the modified T cells would recognise the WT1 protein and attack the leukaemia cells.
Everybody taking part had WT1 TCR gene therapy. Some people had a lower dose. And some people had a higher dose.
The main aims of the trial were to find out:
- the best dose of modified T cells to give
- more about the side effects
- whether the modified T cells recognise leukaemia cells
Summary of results
As part of our editorial policy, any trial information we write is checked externally before we put it on our website. The research team have published some results for this trial. But we have been unable to find anyone involved with the trial to check the summary for us.
This means we are not able to include a plain English summary of the results on this page.
More information
There is more information about this trial in the link to the European trials website below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study
The European Union Clinical Trials Register
Accessed September 2023
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
Chief Investigator
Dr Emma Morris
Supported by
Cell Therapy Catapult
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Last review date
CRUK internal database number:
10903
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
Wendy took part in a new trial studying the possible side effect of hearing loss
